Company Overview

Development Stage

About the Company

DualityBio映恩生物是一家临床阶段的创新生物药公司,专注于为癌症和自身免疫性疾病患者研发新一代ADC治疗药物。映恩生物已成功构建了多个具有全球知识产权的新一代抗体药物偶联物(ADC)技术平台。基于对疾病生物学机制的深入研究和探索,映恩生物已有四个国际多中心(MRCT)临床阶段项目,并拥有十多项处于临床前阶段的创新项目。此外,映恩生物正在继续研发其新型蛋白质工程和ADC技术,以开发下一代“超级ADC”分子,包括不同有效载荷类别、双特异性ADC和双有效载荷ADC。
如需了解更多信息, 请参阅。

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

How Fast Is Hiring Growing? (91 open positions)

Manage
Note: How fast is hiring at 映恩生物科技(上海)有限公司 growing? 2026: 103 openings (up 58%), 2025: 65 openings (up 110%), 2024: 31 openings (up 210%), 2023: 10 openings (flat), 2022: 10 openings. A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

Master's Degree Job Demand Analysis

(More)
?
Growth Rate
2026 vs 2025
  • 2025: Up 170%
  • 2024: Up 43%
  • 2023: Down 13%
Master's Hiring by Year:
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is master's hiring at 映恩生物科技(上海)有限公司 growing? Master's recruitment over the years: 2025: 27 openings (up 170%), 2024: 10 openings (up 43%), 2023: 7 openings (down 13%), 2022: 8 openings.

Doctoral Degree Job Demand Analysis

(More)
+100%
Growth Rate
2026 vs 2025
  • 2025: Down 33%
Doctoral Hiring by Year: 2026 — 4 more jobs than 2025
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is doctoral hiring at 映恩生物科技(上海)有限公司 growing? Doctorate recruitment over the years: 2026: 8 openings (up 100%), 2025: 4 openings (down 33%), 2024: 6 openings.

R&D Strength (Technical Talent Demand)

(More)
How is the demand for technical talent at 映恩生物科技(上海)有限公司? Based on an analysis of 's job postings over the past year, "电子/电器/通信技术类" demand: 43.2%, "计算机/网络/技术类": 36.4%, "医疗卫生/美容保健类": 25.4%, "生物/制药/化工/环保类": 20.3%, "科研类": 12.7%, "其他(研发和技术类)": 2.5%. For reference only.

— What Are the Salaries Like? (118 records)

Manage
salary range: 3K - 50K, 60.1% of roles pay ¥30-50K以上
Note: salary statistics are based on 118 salary records from the past year and depend on the job sample. For reference only.
How is the salary at 映恩生物科技(上海)有限公司?60.1% of positions earn 30-50K以上, Fresh graduate salary: ¥4.3K。Shanghai salary ranking top 35,电子/电器/通信技术类 average salary ¥37.6K。 Note: Based on analysis of job postings, does not represent current on-the-job positions; system stability may affect objectivity. For reference only.Data inaccurate? Let us know

Salaries for hot jobs of

(More)
Are salaries high at 映恩生物科技(上海)有限公司? We provide: ma,ir,ea,pr,oc,te,cto,ra,bi,pe,实习生,科学家,临床,cs,ee,副总,ie,ios,mis,pm. Click to view detailed salary analysis by job.

Related Industry Tags

Tags are auto-annotated by keyword text matching and may be correlated. For reference only.

Job Category

  • 电子/电器/通信技术类
    41.9% of total 41.9%
  • 计算机/网络/技术类
    36.3% of total 36.3%
  • 工厂生产类
    29.8% of total 29.8%
  • 医疗卫生/美容保健类
    25% of total 25%

Education

  • 本科
    43.5% of total 43.5%
  • 硕士
    39.5% of total 39.5%
  • 不限
    7.3% of total 7.3%
  • 博士
    6.5% of total 6.5%

Experience

  • 不限
    50% of total 50%
  • 5-10年
    25% of total 25%
  • 3-5年
    14.5% of total 14.5%
  • 1-3年
    8.1% of total 8.1%
View Detailed Analysis

What does 映恩生物科技(上海)有限公司 require? Who is 映恩生物科技(上海)有限公司 hiring? recruitment: 电子/电器/通信技术类占比最多占41.9%,其次是计算机/网络/技术类占36.3%. What education can get in at ? 本科占比最多占43.5%,其次是硕士占39.5%. High education required at ? 硕士占39.5%,博士占6.5%. Work experience required at ? 不限占比最多占50%,其次是5-10年占25%. Where are the job locations at ? 上海占比最多占72.6%,其次是北京占12.9%. Based on job postings from the past year, for reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 24,000万(元)
Legal Representative: 朱忠远
Date Established:
Credit Code: 91310115MA1K4J0HXF
Registered Address: 中国(上海)自由贸易试验区临港新片区沧海路4188号15幢一层

Partners & Suppliers

映恩生物与BioNTech就两款ADC药物(DB-1303、DB-1311)达成全球合作协议,BioNTech支付预付款及里程碑。 Source
合作客户 药物授权
映恩生物授予百时美施贵宝一款ADC药物(DB-1305等)的全球独家许可,获得预付款及里程碑付款。 Source
合作客户 药物授权
映恩生物授予华东医药一款ADC药物(DB-1303)在中国大陆、香港、澳门的独家开发及商业化权利。 Source
合作客户 药物授权

People who follow this company also follow

Competitors (Similar Companies)

肿瘤治疗 影像系统 内窥镜 造影剂
“An innovative biopharmaceutical enterprise focusing on antibody drugs”
制药/药业 抗体 蛋白质工程 生物制药
电子商务 生产 毛衫 套头毛衣
“Primarily engaged in the R&D, production, and sales of low-voltage ele”
研发 自动化技术 智能照明控制 照明控制
零售 销售 连锁 直营
“一家从事中高档服装设计,开发,生产的工贸一体的专业公司”
“致力于提高动物采食量和消化能力”
软件 CRM 汽车产业链
鸡蛋 鸡苗 蛋鸡苗 有机肥料
“Dedicated to providing high-purity process system solutions for high-e”
光刻胶 聚合物 材料科技 半导体光刻
“光器件整体解决方案提供商和光电先进封装制造服务商”
工程咨询 工程设计 工程总承包/EPC 建筑工程设计

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates